Swiss pharmaceutical company Lonza has, on Feb 9, signed an agreement with private equity bidders Bain Capital and Cinven to divest its Specialty Ingredients business and operations for an enterprise value of CHF4.2 billion ($6.22 billion).

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply